On 16 October, OctoPlus announced that the Board of Supervisory Directorsproposed to expand the Executive Board with two new members. The new Boardwould consist of Chief Executive Officer, Simon Sturge, Joost Holthuis,current CEO and founder, who would take up the new position of ChiefOperating Officer, Chief Financial Officer Hans Pauli and Chief BusinessOfficer Gerben Moolhuizen.

Expansion of the Executive Board to four members and the new division ofresponsibilities will ensure optimal use of expertise and experience toguide the Company to the next level and position OctoPlus for future growthand the building of shareholder value.

During today's Meeting the shareholders approved the appointment of Mr.Sturge and Mr. Moolhuizen as members of the Executive Board.

As a consequence of these appointments, the Executive Board is composed asfollows:

1. Mr. S.J. Sturge (Chief Executive Officer)2. Mr. J.J.M. Holthuis (Chief Operating Officer)3. Mr. J.C.H.L. Pauli (Chief Financial Officer)4. Mr. G. Moolhuizen (Chief Business Officer)

In addition, a change in composition of the Supervisory Board of Directorswas proposed. Current Supervisory Board member René Kuijten was nominatedto be reappointed, and new member Mr. Frans Eelkman Rooda was proposed fornomination. Current chairman Hans Stellingsma and members Philip Smith andPaul Toon will remain on OctoPlus' Board.

During today's Annual General Meeting of Shareholders, the reappointment ofMr. Kuijten and the appointment of Mr. Eelkman Rooda were approved.

As a consequence of this appointment and re-appointment, the Board ofSupervisory Directors is composed as follows:

1. Mr. J. Stellingsma (chairman)2. Mr. Ph.L. Smith3. Mr. R.R. Kuijten4. Mr. P.H.M. Toon5. Mr. F. Eelkman Rooda

All other agenda items of today's Meeting were also approved by theshareholders.

About OctoPlus

OctoPlus N.V. is a product-oriented biopharmaceutical company committed tothe creation of improved pharmaceutical products that are based onOctoPlus' proprietary drug delivery technologies and have fewer sideeffects, improved patient convenience and a better efficacy/safety balancethan existing therapies. Rather than seeking to discover novel drugcandidates through early stage research activities, OctoPlus focuses on thedevelopment of long-acting, controlled release versions of known proteintherapeutics, other drugs, and vaccines on behalf of its clients.

Our pipeline consists of 4 products in pre-clinical and clinicaldevelopment. The lead product incorporating our technology is Locteron, acontrolled release formulation of interferon alfa for the treatment ofchronic hepatitis C, which has been licensed to Biolex Therapeutics and isbeing manufactured by OctoPlus. Locteron is currently in Phase II clinicalstudies. Furthermore, our pipeline comprises a product candidate for thetreatment of chronic middle ear infection, which has completed Phase IIclinical proof of concept, and two pre-clinical-stage single-shot vaccines.

In addition, OctoPlus is a European leading provider of advanced drugformulation and clinical scale manufacturing services to the pharmaceuticaland biotechnology industries, with a focus on difficult-to-formulate activepharmaceutical ingredients.

OctoPlus is listed on Euronext Amsterdam by NYSE Euronext under the symbolOCTO. For more information about OctoPlus, please visit our websitewww.octoplus.nl.

This document may contain certain forward-looking statements relating tothe business, financial performance and results of OctoPlus N.V. and theindustry in which it operates. These statements are based on OctoPlusN.V.'s current plans, estimates and projections, as well as itsexpectations of external conditions and events. In particular the words"expect," "anticipate," "predict," "estimate," "project," "plan," "may,""should," "would," "will," "intend," "believe" and similar expressions areintended to identify forward-looking statements. We caution investors thata number of important factors, and the inherent risks and uncertaintiesthat such statements involve, could cause actual results or outcomes todiffer materially from those expressed in any forward-looking statements.In the event of any inconsistency between an English version and a Dutchversion of this document, the English version will prevail over the Dutchversion.

Press release in PDF formathttp://hugin.info/137076/R/1267339/279617.pdf